Clinical Trial Update: Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating induction chemotherapy with sintilimab plus dual epigenetic drugs for ENKTL-HLH, focusing on safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma Nasal Type with Hemophagocytic Lymphohistiocytosis

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Safety and Efficacy | Phase 2 | Status: UNKNOWN